Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)

被引:2
|
作者
Pothuri, Vikram [1 ]
Rodriguez, Jorge G. Zarate [1 ]
Kasting, Christina [1 ]
Leigh, Natasha [1 ,2 ]
Hawkins, William G. [1 ,2 ]
Sanford, Dominic E. [1 ,2 ]
Fields, Ryan C. [1 ,2 ,3 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Alvin J Siteman Comprehens Canc Ctr, Sch Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave Campus Box 8109, St Louis, MO 63110 USA
关键词
RACIAL DISPARITIES; CANCER;
D O I
10.1016/j.hpb.2023.08.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The impact of neighborhood deprivation on outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) is not well-described and represents an area to improve disparities.Methods: We retrospectively queried our prospectively maintained database of patients with PDAC (2014-2022). Patients were grouped by Area Deprivation Index (ADI) and rural-urban commuting area (RUCA) codes. Cox proportional hazards models and logistic regressions were used to investigate effect on overall survival (OS) and adjuvant therapy administration.Results: 536 patients were included. High ADI patients (more disadvantaged, n = 184) were more likely to identify as non-Hispanic Black (17.9% vs. 4.8%, p < 0.01) and were more likely to be from rural areas (49.5% vs. 18.5%, p < 0.01). High ADI was independently associated with decreased OS (HR (95% CI): 1.31 (1.01-1.69), p = 0.04). Urban high ADI patients were 3.5 times more likely to receive adjuvant therapy than rural high ADI patients (OR [95% CI]: 3.48 [1.26-9.61], p = 0.02).Conclusion: Patients from the most disadvantaged neighborhoods have decreased OS. Access to adjuvant therapy likely contributes to this disparity in rural areas. Investigation into sources of this OS disparity and identification of barriers to adjuvant therapy will be crucial to improve outcomes in un-derserved patients with PDAC.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 50 条
  • [21] Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).
    George, Ben
    Bailey, Mark
    Schrock, Alexa Betzig
    Thorpe, Lauren
    Gay, Laurie M.
    Ritch, Paul S.
    Thomas, James P.
    Erickson, Beth
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Stephens, Philip J.
    Miller, Vincent A.
    Ross, Jeffrey S.
    Singhi, Aatur D.
    Ali, Siraj Mahamed
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [22] Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
    Sell, Naomi M.
    Lee, Grace C.
    Fernandez-Del Castillo, Carlos
    Ferrone, Cristina R.
    Warshaw, Andrew L.
    Hong, Theodore S.
    Blaszkowsky, Lawrence S.
    Lillemoe, Keith D.
    Qadan, Motaz
    PANCREAS, 2020, 49 (07) : 897 - 903
  • [23] Obesity and Pancreatic Ductal Adenocarcinoma (PDAC): A Matched-Pair Survival Analysis
    Teoule, Patrick
    Rahbari, Nuh
    Reissfelder, Christoph
    Birgin, Emrullah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 222 - 222
  • [24] Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
    Shahda, Safi
    Perkins, Susan
    Cramer, Harvey M.
    House, Michael Garrett
    Nakeeb, Attila
    Zyromski, Nicholas J.
    Ceppa, Eugene P.
    Sehdev, Amikar
    Akisik, Fatih
    Lin, Jingmei
    Schmidt, Christian
    Ellsworth, Susannah G.
    O'Neil, Nina
    Link, Kristen
    O'Neil, Bert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma
    Hall, William A.
    Colbert, Lauren E.
    Liu, Yuan
    Gillespie, Theresa
    Lipscomb, Joseph
    Hardy, Claire
    Kooby, David A.
    Prabhu, Roshan S.
    Kauh, John
    Landry, Jerome C.
    CANCER, 2013, 119 (12) : 2350 - 2357
  • [26] The Impact of Sampling on Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy
    Taherian, Mehran
    Katz, Matthew
    Prakash, Laura
    Tong, Yi Tat
    Lai, Zongshan
    Chatterjee, Deyali
    Wang, Hua
    Kim, Michael
    Tzeng, Ching-Wei
    Ikoma, Naruhiko
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene
    Maitra, Anirban
    Wang, Huamin
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1529 - S1530
  • [27] THE IMPACT OF ADJUVANT THERAPY DELAY ON SURVIVAL FOLLOWING PANCREATICODUODENECTOMY FOR PANCREATIC ADENOCARCINOMA
    Kutlu, Onur
    Lee, Jeffrey E.
    de La Cruz, Nestor
    Conrad, Claudius
    GASTROENTEROLOGY, 2017, 152 (05) : S1235 - S1235
  • [28] Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff, Katherine T.
    Gabriel, Emmanuel
    Attwood, Kristopher
    Kuvshinoff, Boris W.
    Nurkin, Steven J.
    Hochwald, Steven N.
    HPB, 2017, 19 (07) : 587 - 594
  • [29] Improved overall survival for patients with early-onset pancreatic ductal adenocarcinoma.
    Nair, Kanika G.
    Kamath, Suneel Deepak
    Wei, Wei
    Tullio, Katherine
    Estfan, Bassam N.
    Khorana, Alok A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [30] Cathepsin D Expression in Pancreatic Ductal Adenocarcinoma (PDAC) Cells Increases Proliferation and Reduces Survival of Pancreatic Cancer Patients
    Mahajan, Ujjwal M.
    Langhoff, Enno
    Costello, Eithne
    Greenhalf, William
    Halloran, Christopher
    Schwaiger, Theresa
    Weiss, Frank-Ulrich
    Neoptolemos, John
    Buchler, Markus W.
    Lerch, Markus M.
    Mayerle, Julia
    GASTROENTEROLOGY, 2015, 148 (04) : S13 - S13